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Abstract
Tumor cells often subvert normal regulatory mechanisms of signal transduction. This study shows
this principle by studying yet uncharacterized mutants of the epidermal growth factor receptor
(EGFR) previously identified in glioblastoma multiforme, which is the most aggressive brain
tumor in adults. Unlike the well-characterized EGFRvIII mutant form, which lacks a portion of the
ligand-binding cleft within the extracellular domain, EGFRvIVa and EGFRvIVb lack internal
segments distal to the intracellular tyrosine kinase domain. By constructing the mutants and by
ectopic expression in naive cells, we show that both mutants confer an oncogenic potential in
vitro, as well as tumorigenic growth in animals. The underlying mechanisms entail constitutive
receptor dimerization and basal activation of the kinase domain, likely through a mechanism that
relieves a restraining molecular fold, along with stabilization due to association with HSP90.
Phospho-proteomic analyses delineated the signaling pathways preferentially engaged by
EGFRvIVb-identified unique substrates. This information, along with remarkable sensitivities to
tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological
interception in brain tumors harboring EGFRvIV mutations.
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Introduction
Growth factors and their receptors control cell-fate decisions, including survival,
differentiation, proliferation or migration, and hence they have critical roles in
hyperproliferative diseases, including malignancies (Hynes and MacDonald, 2009).
Increased availability of growth factors because of either autocrine or paracrine loops and
genetically aberrant forms of the respective cell surface receptors, or their downstream
signaling components, are frequently detected in tumors. A striking example is provided by
the epidermal growth factor (EGF) and the cognate receptor (EGFR, also termed ErbB-1).
The extracellular portion of EGFR is composed of two cysteine-rich domains that form the
ligand-binding cleft (Burgess et al., 2003), whereas the intracellular portion consists of a
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juxtamembrane and a tyrosine kinase domain, followed by a distal carboxyl tail (C-tail) that
undergoes autophosphorylation. Upon ligand binding and consequent kinase activation,
EGFR activates several downstream signaling cascades, such as the mitogen-activated
protein kinase cascade and the phosphoinositol 3-kinase pathway (Katz et al., 2007).
EGFR is commonly overexpressed or mutated in human malignancies, and a close
examination of the mutated areas clearly indicates that these mutations are not randomly
dispersed along the receptor, but are rather concentrated in specific ‘hot spots’ (Ladanyi and
Pao, 2008). Not surprisingly, these frequently mutated domains encompass well-defined
regulatory elements that prevent untimely stimulation of the highly mitogenic downstream
signaling pathways. For example, EGFRvIII, a deletion mutant lacking exons 2–7, including
a portion of the extracellular ligand-binding domain, is commonly found in glioblastoma
multiforme, which is an aggressive form of adult human brain tumors. Approximately 50%
of glial tumors harbor EGFR gene amplification that correlates with receptor overexpression
(Wong et al., 1987), and a large fraction of these also present EGFRvIII (Jeuken et al.,
2009). Despite its inability to bind soluble ligands, EGFRvIII shows constitutive tyrosine
phosphorylation and activation of multiple downstream signaling pathways (Huang et al.,
2009). Indeed, EGFRvIII molecules are basally dimerized and confer a high tumorigenic
potential (Nagane et al., 1996).
Other, less frequent deletion mutations were identified in glioblastoma multiforme. These
mutated receptors present intracellular deletions, but their oncogenic potential remains
hitherto uncharacterized. The carboxyl terminal deletion mutants, collectively termed
EGFRvIV, lack either three exons (numbered 25–27; hereinafter EGFRvIVa) or two exons
(25 and 26; hereinafter EGFRvIVb) (Ekstrand et al., 1992; Frederick et al., 2000; Kuan et
al., 2001), with the deletion initiating immediately downstream to the kinase domain. In this
study we provide the first evidence for the transforming and tumorigenic properties of
carboxyl terminal EGFR deletions. We show that the deletion mutants show ligand-
independent constitutive activation, which engages distinct phosphorylation substrates.
Importantly, the oncogenic function of EGFR harboring these carboxyl terminal deletions
depends upon the intrinsic kinase activity and the chaperoning function of heat shock protein
90 (HSP90). Thus, beyond the demonstration of a novel kinase regulatory mechanism that
depends on a specific carboxyl terminal segment, our findings suggest therapeutic strategies
using EGFR-specific tyrosine kinase inhibitors, and/or HSP90 inhibitors, to target tumors
harboring the EGFRvIV mutations.
Results
EGFRvIV can transform murine fibroblasts
To investigate the putative transforming potentials of the two EGFRvIV mutant forms (see
schematic domain structures in Figure 1a), we constructed the respective retroviral
expression vectors and stably expressed them, along with wild-type (WT) EGFR and the
EGFRvIII mutant, in NIH-3T3 murine fibroblasts. Drug (G418)-resistant cell pools stably
expressing these mutants gained phenotypes consistent with malignant transformation: cells
expressing the mutants showed more rapid proliferation than cells that were infected either
with an empty vector or with a WT-EGFR-encoding vector (Figure 1b). Another feature of
the transformed phenotype, namely altered morphology of NIH-3T3 cells (Pulciani et al.,
1982), paralleled the differences in proliferation rates (Figure 1c): unlike control cells and
cells expressing WT-EGFR, which preserved normal morphology, the shapes showed by
EGFRvIV-expressing cells were consistent with transformation. Importantly, whereas the
morphology of RAS-transformed cells was not affected by an EGFR-specific kinase
inhibitor (AG1478), treatment with AG1478 largely reversed the morphological alterations
associated with all three mutant forms of EGFR. These observations imply dependence of
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the mutant receptors on the intrinsic catalytic activity for the acquisition of transformed
phenotypes.
In line with accelerated cell proliferation and altered morphology, expression of the
EGFRvIVb mutant conferred anchorage-independent growth of cell colonies in a semisolid
(soft agar) medium (Figure 1d), a feature commonly showed by cancer cells. This property
was shared by the EGFRvIII mutant, but not by WT-EGFR. Moreover, upon subcutaneous
injection into nude mice, in contrast to WT-EGFR and NeoR cells, cells expressing either
EGFRvIVa or EGFRvIVb formed tumors, although smaller than those formed by cells
expressing the EGFRvIII mutant (Figure 1e). Although the shorter deletion of EGFRvIVb
resulted in stronger transforming activity than EGFRvIVa, both mutants reflect the growth
inhibitory roles of the C-tail, segments of which are deleted in brain tumors.
The EGFRvIV mutants are basally phosphorylated
Immunoblotting of tumor specimens derived from the xenografts grown subcutaneously in
mice showed that tumors driven by all three EGFR deletion mutants showed detectable
levels of tyrosine phosphorylation (inset in Figure 1e). This observation, along with the
ability of an EGFR kinase inhibitor to reverse the transformed morphology of mutant-
expressing cells (Figure 1c), raised the possibility that constitutive (ligand-independent)
enzymatic activity of the mutant receptors underlies their tumorigenic properties. To
examine this scenario we analyzed the state of receptor phosphorylation in whole extracts
prepared from the cells shown in Figure 1c. Although WT-EGFR presented no tyrosine
phosphorylation in the stably expressing murine fibroblasts, all deletion mutants showed
detectable tyrosine phosphorylation, which was entirely lost upon treatment with AG1478
(Figure 2a). To further investigate the basal phosphorylation state of the mutants, as well as
their relationships to EGF-induced phosphorylation, the status of several tyrosine residues
was examined using antibodies specific to tyrosine-phosphorylated sites of EGFR. This
analysis confirmed high basal phosphorylation of several major tyrosine residues (Figure
2b). Interestingly, treatment with EGF significantly enhanced phosphorylation of both
EGFRvIV mutant forms. However, as expected, phosphorylation of EGFRvIII was not
affected by the ligand (Figure 2b). Using transient expression of EGFRvIVb in human
embryonic kidney (HEK)-293 human kidney cells, a system allowing very high expression
levels, we confirmed basal tyrosine phosphorylation of the mutant at all doses of the
transfected plasmid (Supplementary Figure S1). In contrast, the WT form of EGFR showed
basal phosphorylation only when expressed at very high levels.
To validate the presence of relatively large populations of basally phosphorylated EGFRvIV
mutant receptors in comparison to WT-EGFR, as well as to map the overall
phosphoproteome differences, we applied LC/MS/MS (liquid chromatography tandem mass
spectrometry) methods on extracts isolated from the NIH-3T3 cells ectopically expressing
the different forms of EGFR. In brief, cells were either unstimulated or treated with EGF.
Proteins present in cell extracts were digested and labeled and tyrosine-phosphorylated
peptides were isolated, as previously described (Zhang et al., 2005; Huang et al., 2007). MS/
MS spectra were extracted and quantified and peptide sequences assigned to specific
proteins. Unsupervised examination of the data revealed grouping of samples according to
whether or not cells were exposed to EGF (Supplementary Figure S2 and Excel File). The
only exception was EGFRvIII, which cannot bind EGF. To identify components of the
signaling networks that were either shared or unique to each form of EGFR, a clustering
analysis was performed on phosphopeptides detected under basal (unstimulated) conditions.
This analysis identified three distinct clusters (Figure 2c). The first represents proteins
highly phosphorylated in WTEGFR, but weakly modified in mutant-expressing cells
(denoted cluster 1). Clusters 2 and 3 are enriched for tyrosine-phosphorylated proteins in
EGFRvIVb- and EGFRvIII-expressing cells, respectively. Interestingly, EGFRvIVa showed
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very low levels of phosphoproteins under unstimulated conditions. As seen in Figure 2d, all
three EGFR phosphotyrosine sites we quantified by mass spectrometry were phosphorylated
at significantly higher levels in the mutant-expressing cell lines compared with WT-EGFR
under unstimulated conditions, in line with constitutive activation and the results obtained
using immunoblots (Figures 2a and b).
Constitutive downstream signaling by the EGFRvIV mutants
It is notable that clusters 2 and 3 were derived from unstimulated cells, yet they contained
several signaling proteins, suggesting that the respective mutants activate signaling
pathways in the absence of ligands. Closer analyses of the data revealed mutation-specific
signatures of phosphorylation substrates (Figures 3a and b). For example, EGFRvIVb
(cluster 2) activated STAT3 (signal transducer and activator of transcription 3) to a greater
extent compared with WT-EGFR, EGFRvIII or EGFRvIVa, whereas the EGFRvIII mutant
(cluster 3) preferentially activated another family member, STAT5b. This differential STAT
activation suggests that the mutants activate different cellular programs (Clarkson et al.,
2006). Similarly, the adaptor protein SHC, which physically interacts with active EGFR,
was assigned to cluster 2, with increased phosphorylation by EGFRvIVb and decreased
phosphorylation in the WT-EGFR- and EGFRvIII-expressing cells. The cluster
corresponding to EGFRvIII, however, included three phosphorylation sites of phospholipase
C-γ1 (Y771, Y783 and Y1253) and two phosphorylation sites of AXL (Y696 and Y860), a
mitogenic receptor tyrosine kinase of gliomas (Hafizi and Dahlback, 2006). Taken together,
the two distinct clusters imply that each mutation preferentially activates different
downstream signaling pathways.
To further address the possibility that the relatively high basal kinase activity of the
EGFRvIV mutants leads to constitutive downstream signaling, we focused on SHC and
GRB2 (growth factor receptor-bound protein 2), the two major adaptors linking activated
EGFR to the mitogen-activated protein kinase pathway. In response to stimulation of WT-
EGFR by ligands such as EGF, the receptor forms physical complexes with both adaptors,
as shown in Figure 3c. In the case of the EGFRvIV mutants, complex formation occurred
even in the absence of a stimulating ligand, although larger fractions of GRB2 and SHC
were physically recruited to EGFR on stimulation with EGF. Interestingly, neither
EGFRvIII nor EGFRvVa (a very rare deletion mutant of brain tumors encompassing all
amino acids distal to the kinase domain) showed complex formation with the adaptors, even
in the presence of EGF (Figure 3c). Congruent with these results, we detected constitutive,
although weak, activation of the mitogen-activated protein kinase extracellular signal-
regulated kinases 1 and 2 (and of AKT) in unstimulated cells expressing the EGFRvIV
mutants (Figure 3d). In contrast, cells expressing EGFRvIII showed constitutive activation
of the AKT pathway, rather than the extracellular signal-regulated kinase pathway, in line
with a previous report (Huang et al., 2007), once again supporting our conclusion that
distinct pathways are recruited by EGFRvIII and the EGFRvIV mutants.
One major and early outcome of EGFR activation is the induction of JUN, an oncogenic
transcription factor that participates in the bipartite activator protein-1 complex (Zenz and
Wagner, 2006). Accordingly, immunoblotting for JUN detected enhanced ligand-induced
expression in fibroblasts expressing WT-EGFR (Figure 3e). Conversely, cells expressing the
EGFRvIV or EGFRvIII mutant receptors showed similarly high levels of JUN in the
absence of ligand stimulation. A further increase was achieved upon stimulation of the
EGFRvIV mutants, but no reproducible induction was observed in the EGFRvIII mutant.
Along with activation by EGFR mutants of forward-acting effectors, we expected
inactivation of restraining mechanisms. In line with this prediction, our mass spectrometry
analyses detected in cluster 1 high basal tyrosine phosphorylation of EPHA2, a negative
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regulator of EGFR (Li et al., 2009), in WT-EGFR-expressing cells. However, this signal
was lower in the three lines of mutant-expressing cells (Supplementary Excel File).
Interestingly, EPHA2 was reported to be overexpressed in an unphosphorylated form in
glioblastoma multiforme cells and tumors (Wykosky et al., 2005). To validate differential
tyrosine phosphorylation, we determined the state of EPHA2 modification (Figure 3f). The
results confirmed that tyrosine phosphorylation of EPHA2 is significantly higher in WT-
EGFR-expressing cells than in cells expressing either mutant of EGFR, in agreement with
our mass spectrometry data. Interestingly, the control Neo-resistant cells also showed
reduced EPHA2 phosphorylation levels (Figure 3f), suggesting that EGFR is essential for
phosphorylation of EPHA2, but this restraining module is defected by activating EGFR
mutations.
Constitutive dimerization may underlie the basal phosphorylation of the EGFRvIV mutant
receptors
To investigate the mechanism that underlies basal phosphorylation of the EGFRvIV
mutants, we tested whether this basal activity was due to intrinsic activation or to enhanced
sensitivity to autocrine stimulation by EGF-like ligands, as previously proposed (Ramnarain
et al., 2006). To test the autocrine alternative, stably expressing NIH-3T3 cells were treated
with increasing EGF concentrations (Figure 4a). Quantification of the results showed a
linear response of WT-EGFR phosphorylation to increasing, relatively low (<1.0 ng/ml)
ligand concentrations (Figure 4b). Conversely, EGFR-vIVb was not responsive at this range
of ligand concentrations, yet showed consistent basal activity, and underwent enhanced
phosphorylation upon treatment with higher ligand concentrations (Figures 4a and b). This
observation implies that enhanced sensitivity to EGF may not be the cause for the relatively
high basal phosphorylation observed with the EGFRvIV mutants. Instead, the enhanced
basal phosphorylation of this set of EGFR mutants likely represents intrinsic activation
because of internal deletions of carboxyl terminal segments.
Because the kinase domain of WT-EGFR is intrinsically autoinhibited, and a ligand-induced
dimerization promotes its activation (Zhang et al., 2006), we investigated a model attributing
basal activation of the EGFRvIV mutants to constitutive receptor dimerization. To this end,
we used the more active EGFRvIVb mutant, which was analyzed in two stably expressing
cell lines: murine NIH-3T3 fibroblasts and human U87MG glioma cells. To visualize
receptor dimers, we incubated whole cell extracts with the covalent crosslinking reagent
bis(sulfosuccinimidyl) suberate (BS3) as previously described (Shtiegman et al., 2007). In
addition, because of the low abundance of receptor dimers, we increased sensitivity of
detection using antibodies to the phosphorylated form of tyrosine 1068 of EGFR. Exposure
to EGF of either cell type expressing WT-EGFR verified the ability of BS3 to capture the
otherwise noncovalently associated, reversible receptor dimers, which are strictly dependent
on ligand binding. In contrast, dimers of the EGFRvIII mutant were present independently
of EGF stimulation (Figure 4c). Importantly, the EGFRvIVb mutant receptor expressed in
either cell line showed small populations of basally phosphorylated dimers, which were
dramatically enhanced after treatment with EGF. These observations imply that the more
oncogenic EGFRvIII mutant exists primarily in constitutively active receptor dimers,
whereas only a small fraction of EGFRvIVb exists in active dimers before ligand binding,
which may explain the weaker transforming and autophosphorylating activities of this
mutant.
Structural studies have shown that ligand-induced EGFR dimerization involves major
domain rearrangements in the extracellular part, exposing a critical dimerization arm
(Burgess et al., 2003). Because the observed constitutive dimerization of this mutant is
likely independent of the dimerization arm. To test this hypothesis we introduced a point
mutation (replacement of a glutamate at position 293) in EGFRvIVa, EGFRvIVb and WT-
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EGFR, which impairs formation of receptor dimers mediated through intermolecular
interactions of the extracellular domains (Dawson et al., 2005). The mutant receptors were
transiently expressed in CHO (Chinese hamster ovary) cells, which enable high ectopic
expression on an EGFR-null background. As we previously reported (Tzahar et al., 1996),
when overexpressed in CHO cells, WT-EGFR shows weak tyrosine phosphorylation before
stimulation. Nevertheless, this basal activity was markedly enhanced on EGF treatment
(Figure 4d). Remarkably, the glutamate-to-alanine mutation (E293A) completely abolished
both basal and EGF-inducible tyrosine phosphorylation of WT-EGFR, in line with a
requirement of extracellular domain interfaces for receptor dimerization of WT-EGFR
(Dawson et al., 2005). As expected, both EGFRvIV mutants showed high basal
phosphorylation when overexpressed in CHO cells, but this was not abolished in the
respective E293A mutant forms (Figure 4d). In conclusion, the EGFRvIVb mutant of EGFR
shows relatively high basal phosphorylation, which might be attributed to an intrinsic ability
to form dimers before stimulation with EGF. This intrinsic propensity to dimerize is
independent of the extracellular dimerization arm of EGFR, but may involve the mutated
regions within the cytoplasmic portion of EGFRvIV receptors (see Discussion).
HSP90 regulates stability and activity of the EGFRvIV mutants
Using virally infected murine fibroblasts and human U87MG cells, we observed consistently
higher expression of all mutant forms of EGFR compared with WT receptor, despite
uniformity of experimental conditions. Hence, we hypothesized that a post-translational
mechanism leads to increased stability of mutant EGFRs. It has previously been shown that
constitutively active and oncogenic forms of tyrosine kinases, such as p210BCR-ABL and
v-SRC, are more stringently controlled by HSP90 than their normal cellular counterparts, c-
ABL and c-SRC (An et al., 2000). This observation extends to mutant forms of EGFR
frequently detected in non-small cell lung cancer: mutational activation of several distinct
forms is associated with relatively high basal phosphorylation (Shtiegman et al., 2007), and
with increased dependence on HSP90 for stability (Shimamura et al., 2005). These
considerations predict that HSP90 controls the stability of the EGFRvIV mutants more
stringently than it regulates WT-EGFR. Consistent with this prediction, after treatment with
17-AAG, a specific HSP90 inhibitor (Chiosis et al., 2003), NIH-3T3 cells stably expressing
the vIVb mutant partly lost their transformed phenotype and reverted to a morphology that is
similar to the phenotype of WT-EGFR-expressing cells (Figure 5a). This property was
shared by EGFRvIII, a mutant known to be regulated by HSP90 (Lavictoire et al., 2003). In
line with these observations, after 24 h of HSP90 inhibition, the levels of both EGFRvIV
mutant proteins, similar to the levels of EGFRvIII, significantly decreased, but the level of
WT-EGFR remained largely unaffected, further supporting a stabilizing role toward mutant
receptors. Concomitantly, 17-AAG reduced tyrosine phosphorylation of all three types of
EGFR deletion mutants, under both basal and EGF-stimulated conditions (Figure 5b). In line
with this observation, crosslinking analyses of monomeric and dimeric forms of the vIII and
vIVb mutant forms of EGFR reflected reduced overall phosphorylation, and raised the
possibility that the dimeric form might be more sensitive to 17-AAG than the monomeric
species of both mutants (Supplementary Figure S3A). Taken together with the inferred
necessity for basal tyrosine phosphorylation and sensitivity to a kinase inhibitor (Figure 1c),
the results obtained with 17-AAG imply that the transforming potential of the EGFRvIV
mutants might critically depend not only on the catalytic kinase activity but also on
stabilization by HSP90. This possibility is supported by the experiment presented in
Supplementary Figure S3B: a combination of sub-optimal concentrations of 17-AAG and
AG1478 more effectively normalized the morphology of EGFRvIV-expressing fibroblasts.
If extended to animal models, our biochemical and cellular observations may identify kinase
and chaperone blockers as potential treatment strategies for a subgroup of patients with brain
tumors.
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Discussion
Overexpression of EGFR is one of the most frequently diagnosed genetic aberrations of
glioblastomas, and is often accompanied by deletion mutations. The most frequently
detected and best-studied deletion mutant is EGFRvIII (Gan et al., 2009). This mutated
receptor is highly oncogenic and shares both structural and functional similarities with the
viral EGFR homolog, v-ErbB (Shu et al., 1991). The two EGFRvIV mutants, termed
EGFRvIVa and EGFRvIVb in this study, have so far evaded biochemical investigation.
These mutants lack a significant segment of their noncatalytic carboxyl terminal sequences,
yet their extracellular domain is intact. Interestingly, a similar deletion was uncovered in the
S3v-ErbB strain of the avian erythroblastosis virus, which is more aggressive than other
strains (McManus et al., 1997).
Our results indicate that the internal deletions of EGFRvIV enhance basal kinase activity,
and confer oncogenic phenotypes. In addition, we show that the signaling pathways induced
by these mutations differ from those activated by EGFRvIII. Despite differences, EGFRvIV
and EGFRvIII share some similarities. For example, both activate AKT and decrease
phosphorylation of a negative regulator, EPHA2 (Figure 3). This uncoupling of a negative
feedback loop potentially enhances the transforming receptors. An additional common
property of EGFRvIII and EGFRvIV is their dependence on the chaperoning activity of
HSP90 (Figure 5), which explains the higher abundance of mutated EGFRs relative to WT.
Finally, our results suggest that similar to the case of EGFRvIII, basal dimerization may be
involved in EGFRvIV activation (Figure 4c). Nevertheless, although relief of extracellular
constraints might contribute to dimerization of EGFRvIII, our data favor involvement of the
kinase domain in basal dimerization of EGFRvIV (Figure 4c). It is notable, however, that
the fraction of pre-dimerized EGFRvIII exceeds the portion of EGFRvIV molecules present
within dimers, before EGF binding.
Other receptor tyrosine kinases are regulated by their C-tails (Shewchuk et al., 2000; Chiara
et al., 2004). However, because of its unique independence of phosphorylation within the
activation loop (Gotoh et al., 1992) and because of the fact that the kinase domain of EGFR
does not require large spatial rearrangements to achieve activation (Stamos et al., 2002),
catalytic regulation of this receptor is distinct. On the basis of the structural and
computational analyses, Landau et al. (2004) suggested that a negatively charged segment
(residues 979–996) of the carboxyl terminal region of EGFR forms large complementary
surfaces with the kinase domain and, thereby, may inhibit its catalytic activity. Furthermore,
although they differ in conformation, two crystal structures documented physical
interactions between the kinase domain and carboxyl terminal segments of EGFR: the first
report entails an inactive kinase stabilized by lapatinib, a tyrosine kinase inhibitor (Wood et
al., 2004; see an illustration in Supplementary Figure S4A). Accordingly, two α-helical
regions, 971–980 and 983–990, bind to the kinase domain, potentially inhibiting its
activation. The other structure suggested interactions in trans, in which the C-tail of one
receptor molecule interacts with the kinase of the other receptor, thereby stabilizing an
inactive dimer (Jura et al., 2009) (Supplementary Figure S4B). This inactive conformation is
thought to hinder a kinase–juxtamembrane contact, which is essential for subsequent
activation and kinase–kinase interaction. Taken together, both computational and
crystallographic analyses lend support to the prediction that the naturally occurring
EGFRvIV mutants lack a kinase-inhibitory region, thereby attaining enhanced constitutive
enzymatic activities.
In summary, we conclude that the C-tail distal to the kinase domain of EGFR possesses an
inhibitory role, which interferes with catalytic activation in the absence of ligand-induced
dimerization. Upon deletion in brain tumors, mutant EGFRs acquire basal tyrosine
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phosphorylation that instigates unique sets of signaling proteins, and culminates in
malignant transformation (see model in Figure 6). Intriguingly, the shorter deletion mutant,
namely EGFRvIVb, consistently showed higher kinase and oncogenic activities than the
longer deletion mutant, EGFRvIVa. Future mutational studies will resolve these differences,
along with pinpointing the exact amino acids necessary for kinase regulation.
Materials and methods
Plasmid construction and mutagenesis
A pCDNA3 plasmid containing the complementary DNA of human EGFR was mutated
using QuikChange (Stratagene, La Jolla, CA, USA), with protocol adaptations. In short,
deletions were generated using two primers out-flanking the sequence to be deleted. After a
PCR reaction, DPN I was added, DNA was purified using a PCR purification kit (Qiagene,
Hilden, Germany) and incubated for 30 min with polynucleotide kinase and ATP (Roche,
Mannheim, Germany). The DNA was purified and ligated using T4-DNA ligase. Thereafter,
mutant DNA segments were cloned into the retroviral pLXSN vector and pre-cleaved with
the restriction enzymes BglII and XhoI. pLXSN-V12HRAS was a generous gift from Julian
Downward (London Research Institute, UK). pLRNL-WT-EGFR and U87MG cells were a
generous gift from Frank Furnari (University of California, San Diego, CA, USA).
Gene transfer procedures
Transient plasmid expression was achieved using Lipofectamine (Invitrogen, Carlsbad, CA,
USA). For stable ectopic expression, HEK-293 cells were co-transfected with pLXSN or
pLRNL (5 µg) and a viral packaging plasmid (5 µg). Virus-containing medium was collected
48 h after transfection, mixed with hexadimethrine bromide (5 µg/ml), and the mixture was
incubated with cells for 24 h. Cells were maintained in normal medium for additional 24 h,
followed by selection under G418 (from Gibco BRL, Grand Island, NY, USA; 500 or 600
µg/ml, respectively).
Cell lines and treatments with specific inhibitors
Cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies,
Paisley, UK), supplemented with 10% heat-inactivated fetal calf serum. Cells were
incubated with the EGFR kinase inhibitor, AG1478 (1 µM), or with the HSP90 inhibitor, 17-
AAG (50 nM; Calbiochem, Gibbstown, NJ, USA), in growth medium for 4 days. The
medium of the 17-AAG-treated cells was refreshed daily.
Cell proliferation assay
NIH-3T3 cells were plated in 24-well plates (8000 cells/well), in triplicates. After variable
length incubation, cells were fixed with methanol at −20 °C for 4 min. After methanol
removal, 1ml of methyl violet (0.3%) was added for 20 min at −20 °C. Plates were washed
thoroughly under water and air-dried. Finally, cells were dissolved in 0.2 ml solution of 1N
NaOH and 1% Na-dodecylsulphate, and light absorbance was determined at 570 nm.
Anchorage-independent growth assay
After solidification of a base layer containing growth medium and 0.5% bactoagar (Conda
Laboratories, Madrid, Spain), a mixture of medium, bactoagar (0.42%) and cells (2000) was
spread in triplicates. Digital images were taken after 3 weeks of incubation. Colony
coverage area was calculated using the ImageJ software (NIH, Bethesda, MD, USA, http://
rsb.info.nih.gov/ij/).
Pines et al. Page 8
Oncogene. Author manuscript; available in PMC 2013 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tumor growth in animals
NIH-3T3 cells (2×106 cells per animal) were injected subcutaneously into nude mice (CD-1-
Hfh11-nu; 6-week-old females). Tumor formation was routinely checked and all mice were
killed when the first tumors reached approximately 10% of the total body weight.
Sample preparation, peptide immunoprecipitation and mass spectrometry analyses
In all, 5 million cells were seeded in 15-cm dishes, incubated for 24 h and then serum
starved for 12 h before either treatment without or with EGF (10 ng/ml) for 10 min. For each
of the two biological replicates performed, cells were lysed in 8 M urea and subjected to
reduction, alkylation and trypsin digestion as previously described (Huang et al., 2007).
Peptides were desalted on a C18 Sep-Pak Plus cartridge (Waters, Milford, MA, USA),
eluted with 25% acetonitrile and lyophilized to dryness, Milford, MA, USA. Lyophilized
peptides were subjected to labeling with the iTRAQ 8-plex reagent (Applied Biosystems,
Foster City, CA, USA). Peptide immunoprecipitation was performed as described (Huang et
al., 2007). Immobilized metal affinity chromatography was performed to enrich for
phosphorylated peptides, and peptides retained on the column were eluted with 250 mM
sodium phosphate (pH 8.0) and analyzed by electrospray ionization liquid chromatography
tandem MS on a QqTof (QSTAR Elite, Applied Biosystems) as described (Huang et al.,
2007).
Phosphopeptide sequencing, quantification and clustering
MS/MS spectra were extracted, searched and quantified using Protein Pilot (Applied
Biosystems). Phosphorylation sites and peptide sequence assignments were validated by
manual confirmation of raw MS/MS data. Peak areas of iTRAQ marker ions were
normalized with values from the iTRAQ marker ion peak area of non-phosphorylated
peptides in supernatant of the immunoprecipitation. The data in the Supplementary Excel
File (two sheets) represent the mean and s.d. of phosphopeptides from two biological
replicates normalized to WT-EGFR plus EGF (Supplementary Excel File, sheet 1). Next,
signals corresponding to all phosphotyrosine-containing peptides from unstimulated samples
were centered using the average signal of each peptide across all samples as reference.
Samples were then grouped into three clusters using unsupervised coupled two-way
clustering (Supplementary Excel File, sheet 2) (Getz et al., 2000).
Covalent crosslinking analyses
Cells were starved overnight in serum-free medium, and incubated at 37 1C with EGF (10
ng/ml, unless stated otherwise) for the indicated time intervals. For covalent crosslinking
assays, cells were grown on 10-cm plates, treated with EGF and washed twice with saline.
Thereafter, cells were harvested and incubated for 20 min on ice in lysis buffer containing 2
mM BS3 (Pierce, Rockford, IL, USA). The reaction was quenched by adding glycine (50 mM,
final concentration).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Transforming activities of the EGFRvIV deletion mutants. (a) Schematic representation of
the EGFR deletion mutations that are the main focus of this study. Amino acid numbers are
indicated, along with mutants’ names. (b) NIH-3T3 cells stably expressing the indicated
forms of EGFR (or a vector control; NeoR) were grown for the indicated time intervals and
stained with methyl violet. Optical density was measured after dye dissolution. Averages ±
s.d. (bars) are shown. Inset: an immunoblot of whole lysates of the indicated NIH-3T3 cell
derivatives using an anti-EGFR antibody. (c) NIH-3T3 cells expressing the indicated EGFR
mutants were incubated with either AG1478 (1 µM) or with dimethylsulfoxide (DMSO) as
solvent control. Cells were incubated for 5 days before digital images were taken. Scale bar
= 50 µm. (d) Murine fibroblasts stably expressing the indicated forms of EGFR were plated
in a mixture of agar and medium. Shown images were captured 5 weeks later. Colony
coverage was measured using the ImageJ software. Each box plot is composed of five
horizontal lines that show the 10th, 25th, 50th, 75th and 90th percentiles of the respective
sample. Scale bar=0.5 mm. (e) The indicated stable derivatives of NIH-3T3 cells were
injected subcutaneously into nude mice (2 × 106 cells/animal) and tumor volumes were
measured. Averages ± s.e. (bars) are shown. Inset: an immunoblot of whole lysates of the
indicated NIH-3T3 cell derivatives using an anti-EGFR antibody and an antibody to
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phosphorylated tyrosine 1068 of EGFR. SP, signal peptide; CRD, cysteine-rich domain;
TM, transmembrane; TK, tyrosine kinase.
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Figure 2.
The EGFRvIV mutants are basally phosphorylated. (a) The cells from the experiment shown
in Figure 1c were extracted and subjected to immunoblotting using the indicated antibodies.
(b) NIH-3T3 cells expressing the indicated EGFR mutants were incubated for 10 min
without or with EGF (10 ng/ml), and the phosphorylation status of the indicated tyrosine
residues of EGFR was determined by immunoblotting. (c) Murine fibroblasts ectopically
expressing different forms of human EGFR were lysed, whole extracts were processed and
MS/MS spectra obtained as detailed under Materials and methods. Centered signals of all
phosphotyrosine-containing peptides of the cells were grouped into the indicated three
clusters (see Materials and methods). See Supplementary Excel File (sheet 2). (d) Three
EGFR tyrosine phosphorylation sites were identified by LC/MS/MS: Y1086, Y1148 and
Y1173. The relative phosphorylation levels of the various EGFR forms in the basal state are
indicated.
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Figure 3.
Constitutive signaling by the EGFRvIV mutants. (a, b) Murine fibroblasts ectopically
expressing the indicated forms of EGFR were subjected to phosphoproteomic analyses, and
phosphorylation levels of signaling and adaptor proteins presented as heatmaps. Listed are
specific tyrosine phosphorylation sites of substrates assigned to clusters 2 and 3.
SeeSupplementary Excel File (sheet 1). (c) NIH-3T3 cells expressing the indicated EGFR
mutants were incubated for 10 min without or with EGF. Cell lysates were subjected to
immunoprecipitation (IP) using an antibody to EGFR and immunoblotting (IB) using
antibodies specific to the adaptor proteins SHC and GRB2. Whole cell extracts were also
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analyzed. (d) NIH-3T3 cells expressing the indicated EGFR mutants were incubated for 10
min without or with EGF. Cell lysates were subjected to IB using antibodies to the general
and the phosphorylated forms (pERK and pAKT) of extracellular signal-regulated kinase
(ERK) and AKT. Numbers indicate normalized intensities of phosphorylated bands. (e)
NIH-3T3 cells expressing the indicated EGFR mutants were incubated without or with EGF
(10 ng/ml) for the indicated intervals. The relative levels of JUN were determined by IB
(upper panel). The bands were quantified and normalized according to RAS-GAP. The
dashed line marks the basal level of JUN induction in WT-EGFR-expressing cells. (f)
NIH-3T3 cells expressing the indicated EGFR forms were treated without or with EGF (10
ng/ml; 10 min). Cell lysates were subjected to IP with an antibody directed against
phosphotyrosine (pY) and IB for the EPHA2 receptor.
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Figure 4.
EGFRvIV shows constitutive, but partial, dimerization and autophosphorylation. (a)
NIH-3T3 cells expressing either WT-EGFR or EGFRvIVb were incubated for 20 min with
increasing EGF concentrations. Thereafter, the cells were extracted and analyzed by
immunoblotting (IB) with the indicated antibodies. (b) Phospho-EGFR levels were derived
from (a) by quantifying and normalizing band intensities. The lower panel enlarges the low
range of EGF concentrations shown in the upper panel. (c) U87MG and NIH-3T3 cells
stably expressing the indicated forms of ectopic EGFR were untreated or treated without or
with EGF (10 ng/ml; 10 min). Whole cell extracts were prepared, cleared and incubated
without or with a covalent crosslinking reagent, BS3 (2 mM, 20 min), and subjected to
immunoblotting analysis using an antibody specific to phosphorylated tyrosine 1068 of
EGFR. D and M indicate EGFR dimers and monomers, respectively. (d) WT-EGFR and the
EGFRvIV mutants were mutated at residue 293 (glutamate-to-alanine replacement). CHO
cells were transfected with the indicated EGFR constructs, including double mutants
carrying both the E293A mutation and a deletion, and incubated without or with EGF (10
ng/ml; 10 min). Whole cell extracts were immunoblotted with the indicated antibodies.
Pines et al. Page 18
Oncogene. Author manuscript; available in PMC 2013 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
The EGFRvIV mutants serve as clients of HSP90. (a) NIH-3T3 cells expressing the
indicated forms of EGFR were incubated with either 17-AAG (50 nM; an HSP90 inhibitor)
or with solvent (DMSO). Cells were incubated for 4 days before digital images were taken.
Scale bar = 50 µm. (b) NIH-3T3 cells expressing the indicated EGFR mutants were
incubated without or with 17-AAG (24 h; 50 nM) and without or with EGF (10 min). Cleared
cell extracts were resolved by electrophoresis and immunoblotting with the indicated
antibodies. The lower panels show quantification of total and phospho-EGFR levels,
determined according to band intensities and normalization.
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Figure 6.
A model that compares WT-EGFR and two oncogenic mutants, EGFRvIV and EGFRvIII.
The red circles indicate phosphorylated tyrosine residues; the yellow rectangle marks the
segment missing in the C-tail of EGFRvIV mutants. Unlike EGFRvIII, WT-EGFR and the
EGFRvIV mutants can be stimulated by growth factors. On the other hand, both EGFRvIV
and EGFRvIII show constitutive autophosphorylation that differentiates them from WT-
EGFR and likely enhances aggressiveness of brain tumors.
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